Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FHIT | P49789 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11990409 | 0.90 | L3MBTL1 (0.35) | BRD4SMN1; SMN2FHITL3MBTL1POLB | |
| SCHEMBL11990444 | 0.89 | EPHX2 (0.33) | BRD4SMN1; SMN2FHITCYP3A4MAPT | |
| SCHEMBL11990399 | 0.89 | EPHX2 (0.33) | BRD4SMN1; SMN2FHITCYP3A4MAPT | |
| SCHEMBL11990427 | 0.79 | — | — | |
| SCHEMBL26997852 | 0.74 | BRD4 (0.36) | BRD4SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL11990410 | 0.73 | — | — | |
| SCHEMBL11990387 | 0.73 | — | — | |
| SCHEMBL14091086 | 0.72 | BRD4 (0.41) | BRD4SMN1; SMN2KMT2ATSHRL3MBTL1 | |
| SCHEMBL2463944 | 0.71 | BRD4 (0.37) | BRD4SMN1; SMN2FHITKMT2ATSHR | |
| SCHEMBL11996941 | 0.71 | BRD4 (0.37) | BRD4SMN1; SMN2FHITKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ASANA BIOSCIENCES, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-9044482-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-8865741-B2 | Aminoindane compounds and use thereof in treating pain | ASANA BIOSCIENCES, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | TRPA1, TRPV1, TRPV2 | BRD4 1865/4885SMN1; SMN2 3411/4885FHIT 2685/4885 |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | IDO1, IDO2, SLC1A2 | BRD4 2039/4885SMN1; SMN2 4444/4885FHIT 1236/4885 |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | IDO1, IDO2, SLC1A2 | BRD4 2039/4885SMN1; SMN2 4444/4885FHIT 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.